Last reviewed · How we verify
Low contrast dose CT
At a glance
| Generic name | Low contrast dose CT |
|---|---|
| Also known as | Low contrast medium dosage |
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IC Plus Low-dose Radiation Plus Cadonilimab in LANPC (PHASE3)
- Non-invasive Coronary Thrombus Imaging to Define These Cause of Acute Myocardial Infarction
- Low-Count Quantitative SPECT for Men Treated With Radium-223 (NA)
- Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer (NA)
- Pain in Fibrous Dysplasia (NA)
- Lung Cancer Screening CT for Firefighters (NA)
- Mechanical Dyssynchrony and Microvascular Dysfunction by SPECT
- Parathyroid Adenoma Detection With Rubidium-82 Imaging
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low contrast dose CT CI brief — competitive landscape report
- Low contrast dose CT updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI